Navigation Links
Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA)
Date:7/24/2014

are also leading the effort to advance this formulation for the clinical indication of psoriasis in Taiwan." Dr. KoChung Lin, CEO of PharmaEssentia said, "We are delighted to see the successful collaboration in the allowance for the KX2-391 IND for Actinic Keratosis by US FDA. We are also looking forward to applying for a Taiwan IND for KX2-391 ointment and launching our clinical development program for psoriasis in Taiwan.  Our collaboration with Kinex has been rewarding and we will use our joint momentum to bring KX2-391 Ointment into the clinic in Asia, expeditiously."

KX2-391 is also being developed as an oral agent for oncology indications and has been tested in four clinical studies, thus far.  In defining its pharmacological activity in tumor cells, both in vitro and in vivo,  KX2-391 has been shown to have potent activity against a wide range of solid tumors as well as leukemia cell lines, including cell lines that are resistant to commonly used cancer drugs. Kinex has also partnered with Hanmi Pharmaceuticals (Seoul, Korea) to develop the oral formulation of KX2-391 for oncology indications in the Korea and greater China Territory. In partnership with Hanmi Pharmaceuticals, the safety, tolerability and pharmacokinetics of KX2-391 have been studied in more than 120 patients in both solid and liquid tumors. A study of KX2-391 in combination with paclitaxel is currently being conducted in South Korea and sponsored through the collaboration with Hanmi Pharmaceuticals. 

Dr. Wing Kai Chan, Head of Clinical Operations for Asia Pacific for Kinex, said, "The ability to develop the new topical formulation of KX2-391 for hyper-proliferative skin diseases shows how Kinex is effectively building up its pipeline of drug candidates.  I look f
'/>"/>

SOURCE Kinex Pharmaceuticals
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Kinex Pharmaceuticals Announced that the U.S. Food and Drug Administration has Granted Orphan Drug Status to KX02 for the Treatment of Gliomas
2. Kinex Announces First Patient Dosed in Phase Ib Study of Oraxol, an Orally Dosed Paclitaxel
3. Hanmi Pharmaceuticals to Assign the Rights to Five New Territories to Kinex as Part of the Orascovery Program Strategic Plan
4. Dr. David Hangauer, Chief Scientific Officer and Co-Founder, commits his career to Kinex Pharmaceuticals
5. Kinex Receives Research Support from the Hong Kong Innovation and Technology Commission (ITC)
6. Kinex Announces that the US FDA Allows their IND for Oraxol, an Oral Form of Paclitaxel that is in Phase II Clinical Trials in Korea, to Begin Clinical Trials in the US
7. Kinex Pharmaceuticals Will Take the Lead in the Orascovery Program Development in China
8. Kinex Announces that the US FDA Allows their IND to Begin KX02 Clinical Trials
9. Kinex Pharmaceuticals and Zenith Technology Corporation announce the execution of a collaborative licensing agreement
10. Kinex Pharmaceuticals Chief Scientific Officer, Dr. David Hangauer, named the American Cancer Societys 2013 Honoree for its Cuisine for a Cure event
11. Hanmi and Kinex Announced Korean FDA Allowance of the KX01 IND Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... – Small Cap IR issues report. Recently, Arrayit Corporation ... blood card technology to Vivos, Global Genome Vault, the ... an impervious, impenetrable and permanent DNA storage vault, able ... Earth, a safe and secure nuclear blast-proof, underground shelter ... rapid collection, separation, drying and storage of human genomic ...
(Date:6/30/2015)... N.C. , June 30, 2015  Marken, the ... to the life sciences industry, has been granted permission ... patient shipment of clinical drug product in Korea.  This ... South Korea to continue receiving their clinical ... System (MERS). The emergency was caused by ...
(Date:6/30/2015)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announces ... of StockholdersWhen:Tuesday, June 30 at 5:10 p.m. ET / ... log onto our website listed above.   ... event, a replay of the webcast will be available ... ABOUT ISIS PHARMACEUTICALS, INC. Isis is ...
Breaking Medicine Technology:Small Cap IR - Empowering the Age of Genetic Enlightenment 2Marken Delivers Direct To Patients During MERS Outbreak 2Marken Delivers Direct To Patients During MERS Outbreak 3Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting 2Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting 3
... Feb. 23 MAP,Pharmaceuticals, Inc. (Nasdaq: ... 3 clinical trial of Unit Dose Budesonide (UDB) ... The Company announced that the clinical,trial did not ... by,changes from baseline in nighttime and daytime composite ...
... BCRX ) today announced that the full ... peramivir in patients hospitalized for influenza was presented by ... Professor, Divisions of Infectious Diseases and Organ Transplantation at ... the XI International Symposium on Respiratory Viral Infections taking ...
Cached Medicine Technology:MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 2MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 3Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 2Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 3Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 4Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 5
(Date:6/30/2015)... , ... June 30, 2015 , ... According to a ... 2007 to 2013 while heroin-related deaths more than tripled in the same period—leading a ... Novus Medical Detox Center , a leading Florida-based drug treatment facility, asserts that ...
(Date:6/30/2015)... ... 30, 2015 , ... ADVOCATE, the premier provider of radiology ... exclusive billing agreements with Jackson Radiology Associates in Jackson, TN. , ... of billing process software functionality called Experience Based Technology (EBTTM). EBTTM improves ...
(Date:6/30/2015)... ... ... On June 26, 2015, Harper’s Bazaar Magazine in an article titled “5 ... not expect to cause acne flare-ups. The list includes pillowcases, cell phones, ... are clogged pores and bacteria and each of the named triggers unexpectedly creates a ...
(Date:6/30/2015)... Jacksonville, FL (PRWEB) , ... June 30, 2015 ... ... in Jacksonville, reported today it has more than doubled the size of its ... , The center’s medical staff -- which includes physicians, nurse practitioners and physician ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... 26th Annual Alzheimer's Association of Colorado's Education Symposium on November 9, 2015 at ... is honored to host a conversation with Kim and Ashley Campbell, the wife ...
Breaking Medicine News(10 mins):Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 2Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 3Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 4Health News:ADVOCATE Wins Billing Agreements with Jackson Radiology Associates 2Health News:A List of 5 Surprising Acne Triggers and the Latest Acne Treatment Options 2Health News:Lakeview Health, a Nationally Recognized Drug Rehabilitation Center in Florida, Doubles Size of Medical Staff 2Health News:Family of Singer Glen Campbell to Discuss Living with Dementia at the Alzheimer's Association of Colorado's 26th Annual Education Symposium 2
... to Focus on G-Protein Coupled Receptors, BERWYN, ... discovery,company focused on developing pharmaceutical products targeting G-protein,coupled ... $24 million,Series A financing. Alta Partners and Healthcare ... syndicate that included New Enterprise Associates and,Polaris Venture ...
... GAINESVILLE, Fla., March 5 In a strange ... new, non-surgical infertility treatment started,reporting unusual side-effects: increased ... reproductive tract adhesions, caused,unexpected results in some patients ... physical therapist Belinda Wurn. (see, http://www.clearpassage.com ), ...
... have discovered an Antarctic fish species that adopts a ... week in the journal PLoS ONE, the online journal ... Antarctic Survey (BAS) and the University of Birmingham reveal, ... coriiceps effectively puts itself on ice to survive the ...
... Calif., March 5 "I have never,experienced greater satisfaction ... cells.", The quote, from Greg Smith, CEO, Mountain ... the storage of umbilical cord blood by,CorCell, Philadelphia, Pa., ... Mr. Smith continues: "The thought of possibly protecting ...
... entered into by,Airborne Health, Inc. - the maker of ... In that settlement, Airborne,Health, Inc. agreed to pay approximately ... California. The settlement has been reported in the,national media ... Airborne Health,Inc., But there is more to the ...
... Secretary of Health,Dr. Calvin B. Johnson met with ... to discuss Governor Edward G. Rendell,s plan to ... of uninsured adults,through his "Cover All Pennsylvanians" proposal., ... help prevent disease,successfully manage chronic diseases such as ...
Cached Medicine News:Health News:Trevena, Inc. Announces $24 Million Series A Financing 2Health News:Trevena, Inc. Announces $24 Million Series A Financing 3Health News:Surprise Orgasms Baffle Women Undergoing New Infertility Treatment 2Health News:Hibernation-like behavior in Antarctic fish -- on ice for winter 2Health News:Greatest Satisfaction Preserving Granddaughter's Cord Blood Stem Cells 2Health News:Information About The Airborne Health, Inc. Settlement, and Other Ongoing Litigation Alleging False and Deceptive Marketing Of Airborne(R) 2Health News:Information About The Airborne Health, Inc. Settlement, and Other Ongoing Litigation Alleging False and Deceptive Marketing Of Airborne(R) 3Health News:Health Secretary Stops in Erie County to Call for Health Insurance for all Pennsylvanians 2
... are an ophthalmologic medical device designed for ... -1.00 to -3.00 diopters.* When placed in ... central optical zone, the product reshapes the ... is composed of two prescription inserts, each ...
... is our most affordable basic centrifuge. The 614 is ... 614 is also the quietest small lab centrifuge on ... up to six (6) test tubes up to 15ml ... lid safety switch and is UL/CSA compliant. ...
... is a simple one, help physicians serve ... image, the physician is provided with significantly ... structures. This technical accomplishment is combined with ... The device features: ...
... Contour Eyelid Implants feature a proprietary ... of the ocular globe. The Contour ... in the eyelid because the tapered lower ... lower profile. Surfaces and edges of the ...
Medicine Products: